2-((2-methylbenzyl)thio)-1H-benzo[d]imidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-((2-methylbenzyl)thio)-1H-benzo[d]imidazole
• 英文别名: 2-[(2-methylphenyl)methylsulfanyl]-1H-benzimidazole
• 化学式: C₁₅H₁₄N₂S
• 分子量: 254.356
• InChiKey: CBPUCSYOOOKPCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  54
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-((2-methylbenzyl)thio)-1H-benzo[d]imidazole 在 sodium hypochlorite 、 sodium hydroxide 作用下， 以 水 、 乙酸乙酯 为溶剂， 以69.8%的产率得到2-((2-methylbenzyl)sulfinyl)-1H-benzo[d]imidazole
  参考文献：
  名称：

  Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction

  摘要：

  Genetic rearrangements of the mixed lineage leukemia (MLL) leading to oncogenic MLL-fusion proteins (MLL-FPs). MLL-FPs occur in about 10% of acute leukemias and are associated with dismal prognosis and treatment outcomes which emphasized the need for new therapeutic strategies. In present study, by a cell-based screening in-house compound collection, we disclosed that Rabeprazole specially inhibited the proliferation of leukemia cells harboring MLL-FPs with little toxicity to non-MLL cells. Mechanism study showed Rabeprazole down-regulated the transcription of MLL-FPs related Hox and Meis1 genes and effectively inhibited MLL1 H3K4 methyltransferase (HMT) activity in MV4-11 cells bearing MLL-AF4 fusion protein. Displacement of MLL1 probe from WDR5 protein suggested that Rabeprazole may inhibit MLL1 HMT activity through disturbing MLL1-WDR5 protein-protein interaction. Moreover, other proton pump inhibitors (PPIs) also indicated the inhibition activity of MLL1-WDR5. Preliminary SARs showed the structural characteristics of PPIs were also essential for the activities of MLL1-WDR5 inhibition. Our results indicated the drug reposition of PPIs for MLL-rearranged leukemias and provided new insight for further optimization of targeting MLL1 methyltransferase activity, the MLL1-WDR5 interaction or WDR5. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.112027
• 作为产物：
  描述：

  邻甲基氯化苄 、 1H-苯并咪唑-2-硫醇 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 2-((2-methylbenzyl)thio)-1H-benzo[d]imidazole
  参考文献：
  名称：

  Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction

  摘要：

  Genetic rearrangements of the mixed lineage leukemia (MLL) leading to oncogenic MLL-fusion proteins (MLL-FPs). MLL-FPs occur in about 10% of acute leukemias and are associated with dismal prognosis and treatment outcomes which emphasized the need for new therapeutic strategies. In present study, by a cell-based screening in-house compound collection, we disclosed that Rabeprazole specially inhibited the proliferation of leukemia cells harboring MLL-FPs with little toxicity to non-MLL cells. Mechanism study showed Rabeprazole down-regulated the transcription of MLL-FPs related Hox and Meis1 genes and effectively inhibited MLL1 H3K4 methyltransferase (HMT) activity in MV4-11 cells bearing MLL-AF4 fusion protein. Displacement of MLL1 probe from WDR5 protein suggested that Rabeprazole may inhibit MLL1 HMT activity through disturbing MLL1-WDR5 protein-protein interaction. Moreover, other proton pump inhibitors (PPIs) also indicated the inhibition activity of MLL1-WDR5. Preliminary SARs showed the structural characteristics of PPIs were also essential for the activities of MLL1-WDR5 inhibition. Our results indicated the drug reposition of PPIs for MLL-rearranged leukemias and provided new insight for further optimization of targeting MLL1 methyltransferase activity, the MLL1-WDR5 interaction or WDR5. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.112027

文献信息

• Three‐Component Synthesis of 2‐Substituted Thiobenzoazoles Using Tetramethyl Thiuram Monosulfide (TMTM) as Thiocarbonyl Surrogate
  作者：Xi Wang、Chun‐Yan Wu、Yue‐Sheng Li、Zhi‐Bing Dong

  DOI：10.1002/ejoc.202001214

  日期：2020.11.22

  A metal‐free synthesis of 2‐benzyl/allyl‐substituted thiobenzoazoles was developed starting from tetramethyl thiuram monosulfide (TMTM) which served as thiocarbonyl surrogate. By using 2‐aminophenols (or 2‐aminothiophenols, or 1,2‐phenylenediamines) and TMTM as starting materials, 2‐mercaptobenzoazoles could be synthesized efficiently, and the subsequent C–S bond formation with allyl/benzyl halides

  从用作硫代羰基替代物的四甲基秋兰姆单硫化物（TMTM）出发，开发了2-苄基/烯丙基取代的硫代苯并恶唑的无金属合成方法。通过使用2-氨基苯酚（或2-氨基硫酚或1,2-苯二胺）和TMTM作为起始原料，可以高效合成2-巯基苯并恶唑，随后与烯丙基/苄基卤化物的CS键形成最终产物（ 2-烯丙基/苄基取代的硫代苯并唑），具有良好或优异的收率。
• One-Pot Synthesis of 2-Benzyl/2-Allyl-Substituted Thiobenzoazoles Using Transition-Metal-Free Conditions in Water
  作者：Shi-Bo Zhang、Xing Liu、Ming-Yuan Gao、Zhi-Bing Dong

  DOI：10.1021/acs.joc.8b02136

  日期：2018.12.21

  A transition-metal-free protocol for the one-pot synthesis of 2-benzyl/2-allyl-substituted thiobenzoazoles in water was developed. The cyclization of 2-aminothiophenols, 2-aminophenols, and 1,2-phenylenediamines with tetramethylthiuram disulfide (TMTD) gave mercapto benzoheterocycles, and the subsequent C-S coupling with benzyl or allyl halides furnished the desired products in good to excellent yields. This method features transition-metal-free conditions with water as a solvent, an easy performance, mild reaction conditions, a wide substrate scope, and good to excellent yields, thus paving an efficient and useful way to establish a library of potentially active drug molecules.
• Synthesis and Spectral Characterization of 2-Mercaptobenzimidazole Derivatives Using a new Active Phase Transfer Reagent Under PTC Conditions
  作者：J. Paul Jayachandran、Maw-Ling Wang

  DOI：10.1080/00397919908085883

  日期：1999.12.1

  The phase transfer catalyzed synthesis of 2-Mercaptobenzimidazole derivatives using the new active phase transfer reagent namely, 2-benzilidine-N,N,N,N',N",N'-hexaethyl propane-1,3-diammonium dibromide (Dq-Br) have been described. The structures of all the fifteen compounds have been established by spectroscopic means.
• Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction
  作者：Wei-Lin Chen、Dong-Dong Li、Xin Chen、Ying-Zhe Wang、Jun-Jie Xu、Zheng-Yu Jiang、Qi-Dong You、Xiao-Ke Guo

  DOI：10.1016/j.ejmech.2019.112027

  日期：2020.2

  Genetic rearrangements of the mixed lineage leukemia (MLL) leading to oncogenic MLL-fusion proteins (MLL-FPs). MLL-FPs occur in about 10% of acute leukemias and are associated with dismal prognosis and treatment outcomes which emphasized the need for new therapeutic strategies. In present study, by a cell-based screening in-house compound collection, we disclosed that Rabeprazole specially inhibited the proliferation of leukemia cells harboring MLL-FPs with little toxicity to non-MLL cells. Mechanism study showed Rabeprazole down-regulated the transcription of MLL-FPs related Hox and Meis1 genes and effectively inhibited MLL1 H3K4 methyltransferase (HMT) activity in MV4-11 cells bearing MLL-AF4 fusion protein. Displacement of MLL1 probe from WDR5 protein suggested that Rabeprazole may inhibit MLL1 HMT activity through disturbing MLL1-WDR5 protein-protein interaction. Moreover, other proton pump inhibitors (PPIs) also indicated the inhibition activity of MLL1-WDR5. Preliminary SARs showed the structural characteristics of PPIs were also essential for the activities of MLL1-WDR5 inhibition. Our results indicated the drug reposition of PPIs for MLL-rearranged leukemias and provided new insight for further optimization of targeting MLL1 methyltransferase activity, the MLL1-WDR5 interaction or WDR5. (C) 2020 Elsevier Masson SAS. All rights reserved.